Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

doi:10.1007/s11684-021-0891-0

Front. Med.

2022, Vol. 16

Issue (5) : 815-826 https://doi.org/10.1007/s11684-021-0891-0

CONSENSUS

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

Suning Chen^1,², Weili Zhao³, Jianyong Li⁴(

), Depei Wu^1,²(

), on behalf of Lymphoid Disease Group, Chinese Society of Hematology, Chinese Medical Association¹

¹. National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China
². Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China
³. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
⁴. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China

Download: PDF(2511 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Oral drugs such as ibrutinib play an important role in the treatment of mature B-cell lymphoma (BCL) due to their reliable efficacy, manageable safety, high accessibility, and convenience for use. Still, no guidelines or consensus focusing on oral drug therapies for BCL is available. To provide a reference of oral agent-based treatment for mature BCL, a panel of experts from the Lymphocyte Disease Group, Chinese Society of Hematology, Chinese Medical Association conducted an extensive discussion and reached a consensus on oral drugs for Chinese BCL patients on the basis of the current application status of oral drugs in China, combined with the latest authoritative guidelines in the world and current research reports. This consensus reviewed the application of oral drugs in the treatment of BCL and the latest research and provided appropriate recommendations on the use of oral drugs for indolent or aggressive BCL patients. With the deepening of research and the development of standardized clinical applications, oral medications will bring better treatment to BCL patients, enabling more patients to benefit from them.

Keywords B-cell lymphoma oral drug targeted therapy immunotherapy COVID-19 pandemic

Corresponding Author(s): Jianyong Li,Depei Wu

Just Accepted Date: 06 July 2022 Online First Date: 22 September 2022 Issue Date: 18 November 2022

Cite this article:

Suning Chen,Weili Zhao,Jianyong Li, et al. Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)[J]. Front. Med., 2022, 16(5): 815-826.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-021-0891-0
https://academic.hep.com.cn/fmd/EN/Y2022/V16/I5/815

Fig.1 Flowchart of oral drug treatment for mature B-cell lymphoma (BCL).

Tab.1 Summary of oral drugs for BCL^a

1	Office of the National Health Commission of the people’s Republic of China General, of the National Administration of Traditional Chinese Medicine Office. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition). China Medicine 2020; 15( 6): 801– 805
2	Working Committee of Chinese Society of Clinical Oncology Guidelines. Lymphoid Malignancies (2020 edition). Beijing: People’s Medical Publishing House, 2020
3	NCCN Guidelines Insights: B-Cell Lymphomas, Version 2.2020. 2020. Available at NCCN website
4	WG Wierda, JC Byrd, JS Abramson, SF Bilgrami, G Bociek, D Brander, J Brown, AA Chanan-Khan, JC Chavez, SE Coutre, RS Davis, CD Fletcher, B Hill, BS Kahl, M Kamdar, LD Kaplan, N Khan, TJ Kipps, MS Lim, S Ma, S Malek, A Mato, C Mosse, M Shadman, T Siddiqi, D Stephens, S Sundaram, N Wagner, M Dwyer, H Sundar. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020; 18( 2): 185– 217 pmid: 32023533
5	Clinical Practice Guidelines in Oncology NCCN. Waldenström’s macroglobulinemia/lymphoplasmacytic lymphoma. Version 1.2021. Fort Washington: National Comprehensive Cancer Network, 2021
6	M Dreyling, E Campo, O Hermine, M Jerkeman, Gouill S Le, S Rule, O Shpilberg, J Walewski, M; ESMO Guidelines Committee Ladetto. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28( suppl_4): iv62– iv71 https://doi.org/10.1093/annonc/mdx223 pmid: 28881919
7	DH Yoon, J Cao, TY Chen, K Izutsu, SJ Kim, YL Kwong, TY Lin, LS Thye, B Xu, DH Yang, WS Kim. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. J Hematol Oncol 2020; 13( 1): 21 https://doi.org/10.1186/s13045-020-00855-9 pmid: 32183871
8	MJ Hassett, MR Somerfield, ER Baker, F Cardoso, KJ Kansal, DC Kwait, JK Plichta, C Ricker, A Roshal, KJ Ruddy, JD Safer, C Van Poznak, RL Yung, SH Giordano. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020; 38( 16): 1849– 1863 https://doi.org/10.1200/JCO.19.03120 pmid: 32058842
9	SS Neelapu, S Adkins, SM Ansell, J Brody, MS Cairo, JW Friedberg, JP Kline, R Levy, DL Porter, K van Besien, M Werner, MR Bishop. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. J Immunother Cancer 2020; 8( 2): e001235 https://doi.org/10.1136/jitc-2020-001235 pmid: 33361336
10	SH Swerdlow, E Campo, SA Pileri, NL Harris, H Stein, R Siebert, R Advani, M Ghielmini, GA Salles, AD Zelenetz, ES Jaffe. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127( 20): 2375– 2390 https://doi.org/10.1182/blood-2016-01-643569 pmid: 26980727
11	KR Shankland, JO Armitage, BW Hancock. Non-Hodgkin lymphoma. Lancet 2012; 380( 9844): 848– 857 https://doi.org/10.1016/S0140-6736(12)60605-9 pmid: 22835603
12	S Pal Singh, F Dammeijer, RW Hendriks. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer 2018; 17( 1): 57 https://doi.org/10.1186/s12943-018-0779-z pmid: 29455639
13	S Ponader, JA Burger. Bruton’s tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol 2014; 32( 17): 1830– 1839 https://doi.org/10.1200/JCO.2013.53.1046 pmid: 24778403
14	R Mcculloch S Rule TA Eyre. Ibrutinib at first relapse for mantle cell lymphoma: a United Kingdom real world analysis of outcomes in 169 patients. Washington, DC: American Society of Hematology, 2019
15	L Karlin H Besson C Tapprich. Efficacy of ibrutinib-rituximab versus real-world (RW) treatments for patients with Waldenström’s macroglobulinemia (WM): adjusted comparison of iNNOVATE and the Lyon-Sud RW Database. Blood 2018; 132( Supplement 1): 1604
16	J Sharman S Kabadi J Clark ES Amirian DJ Andorsky. Treatment patterns and outcomes of 159 ibrutinib-treated MCL patients in the United States: a retrospective electronic medical record database and chart review study. Blood 2018; 132( Supplement 1): 4163 doi:10.1182/blood-2018–99-118848
17	G Salles E Callet-Bauchu H Besson. Single-agent ibrutinib vs real-world (RW) treatments for patients with chronic lymphocytic leukemia (CLL) and del11q: adjusted comparison of RESONATE-2TM and RESONATETM with RW Databases. Blood 2018; 132( Supplement 1): 4427
18	JG Gribben, N Fowler, F Morschhauser. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol 2015; 33( 25): 2803– 2811 https://doi.org/10.1200/JCO.2014.59.5363 pmid: 26195701
19	H Gill, WY Au, WW Cheung, EY Lee, YL Kwong. Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma. Ann Oncol 2014; 25( 7): 1391– 1397 https://doi.org/10.1093/annonc/mdu142 pmid: 24728036
20	Clinical Practice Guidelines in Oncology NCCN. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 2.2021. Fort Washington: National Comprehensive Cancer Network, 2021
21	JA Burger, MJ Keating, WG Wierda, E Hartmann, J Hoellenriegel, NY Rosin, Weerdt I de, G Jeyakumar, A Ferrajoli, M Cardenas-Turanzas, S Lerner, JL Jorgensen, GM Nogueras-González, G Zacharian, X Huang, H Kantarjian, N Garg, A Rosenwald, S O’Brien. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014; 15( 10): 1090– 1099 https://doi.org/10.1016/S1470-2045(14)70335-3 pmid: 25150798
22	JC Byrd, JR Brown, S O’Brien, JC Barrientos, NE Kay, NM Reddy, S Coutre, CS Tam, SP Mulligan, U Jaeger, S Devereux, PM Barr, RR Furman, TJ Kipps, F Cymbalista, C Pocock, P Thornton, F Caligaris-Cappio, T Robak, J Delgado, SJ Schuster, M Montillo, A Schuh, Vos S de, D Gill, A Bloor, C Dearden, C Moreno, JJ Jones, AD Chu, M Fardis, J McGreivy, F Clow, DF James, P; RESONATE Investigators Hillmen. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371( 3): 213– 223 https://doi.org/10.1056/NEJMoa1400376 pmid: 24881631
23	JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, P Hillmen, NL Bartlett, J Li, D Simpson, S Grosicki, S Devereux, H McCarthy, S Coutre, H Quach, G Gaidano, Z Maslyak, DA Stevens, A Janssens, F Offner, J Mayer, M O’Dwyer, A Hellmann, A Schuh, T Siddiqi, A Polliack, CS Tam, D Suri, M Cheng, F Clow, L Styles, DF James, TJ; RESONATE-2 Investigators Kipps. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015; 373( 25): 2425– 2437 https://doi.org/10.1056/NEJMoa1509388 pmid: 26639149
24	M Dreyling, W Jurczak, M Jerkeman, RS Silva, C Rusconi, M Trneny, F Offner, D Caballero, C Joao, M Witzens-Harig, G Hess, I Bence-Bruckler, SG Cho, J Bothos, JD Goldberg, C Enny, S Traina, S Balasubramanian, N Bandyopadhyay, S Sun, J Vermeulen, A Rizo, S Rule. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 2016; 387( 10020): 770– 778 https://doi.org/10.1016/S0140-6736(15)00667-4 pmid: 26673811
25	T Munir, JR Brown, S O’Brien, JC Barrientos, PM Barr, NM Reddy, S Coutre, CS Tam, SP Mulligan, U Jaeger, TJ Kipps, C Moreno, M Montillo, JA Burger, JC Byrd, P Hillmen, S Dai, A Szoke, JP Dean, JA Woyach. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 2019; 94( 12): 1353– 1363 https://doi.org/10.1002/ajh.25638 pmid: 31512258
26	JA Burger, PM Barr, T Robak, C Owen, P Ghia, A Tedeschi, O Bairey, P Hillmen, SE Coutre, S Devereux, S Grosicki, H McCarthy, D Simpson, F Offner, C Moreno, S Dai, I Lal, JP Dean, TJ Kipps. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 2020; 34( 3): 787– 798 https://doi.org/10.1038/s41375-019-0602-x pmid: 31628428
27	JC Byrd, RR Furman, SE Coutre, IW Flinn, JA Burger, K Blum, JP Sharman, W Wierda, W Zhao, NA Heerema, Y Luan, EA Liu, JP Dean, S O’Brien. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 study. Clin Cancer Res 2020; 26( 15): 3918– 3927 https://doi.org/10.1158/1078-0432.CCR-19-2856 pmid: 32209572
28	W Xu, S Yang, K Zhou, L Pan, Z Li, J Zhou, S Gao, D Zhou, J Hu, R Feng, H Huang, M Ji, H Guo, J Huang, W Novotny, S Feng, J Li. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. J Hematol Oncol 2020; 13( 1): 48 https://doi.org/10.1186/s13045-020-00884-4 pmid: 32393328
29	P Strati, K Takahashi, CB Peterson, MJ Keating, PA Thompson, NG Daver, N Jain, JA Burger, Z Estrov, SM O’Brien, HM Kantarjian, WG Wierda, PA Futreal, A Ferrajoli. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv 2019; 3( 9): 1533– 1539 https://doi.org/10.1182/bloodadvances.2019031336 pmid: 31076409
30	Oncology Committee of China Anti-Cancer Association Hematology & Lymphoma Group Society of Hematology at Chinese Medical Association Leukemia for China Lymphoma Investigators Union. The consensus of the diagnosis and treatment of lymphoplasmacytic lymphoma/Walderström macroglobulinemia in China (2016 version). Chin J Hematol (Zhonghua Xue Ye Xue Za Zhi) 2016; 37(9): 729– 734 (in Chinese)
31	SP Treon, CK Tripsas, K Meid, D Warren, G Varma, R Green, KV Argyropoulos, G Yang, Y Cao, L Xu, CJ Patterson, S Rodig, JL Zehnder, JC Aster, NL Harris, S Kanan, I Ghobrial, JJ Castillo, JP Laubach, ZR Hunter, Z Salman, J Li, M Cheng, F Clow, T Graef, ML Palomba, RH Advani. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med 2015; 372( 15): 1430– 1440 https://doi.org/10.1056/NEJMoa1501548 pmid: 25853747
32	MA Dimopoulos, J Trotman, A Tedeschi, JV Matous, D Macdonald, C Tam, O Tournilhac, S Ma, A Oriol, LT Heffner, C Shustik, R García-Sanz, RF Cornell, Larrea CF de, JJ Castillo, M Granell, MC Kyrtsonis, V Leblond, A Symeonidis, E Kastritis, P Singh, J Li, T Graef, E Bilotti, S Treon, C; the iNNOVATE Study Group Buske, European Consortium for Waldenström's Macroglobulinemia the. Ibrutinib for patients with rituximab-refractory Waldenström’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol 2017; 18( 2): 241– 250 https://doi.org/10.1016/S1470-2045(16)30632-5 pmid: 27956157
33	CS Tam S Opat S D’Sa W Jurczak HP Lee G Cull RG Owen P Marlton BE Wahlin RG Sanz H McCarthy S Mulligan A Tedeschi JJ Castillo J Czyz de Larrea C Fernandez D Belada E Libby JV Matous M Motta T Siddiqi M Tani M Trneny MC Minnema C Buske V Leblond J Trotman WY Chan J Schneider S Ro A Cohen J Huang M Dimopoulos. ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM). J Clin Oncol 2020; 38( 15 suppl): 8007 doi:10.1200/JCO.2020.38.15_suppl.8007
34	CS Tam, S Opat, S D’Sa, W Jurczak, HP Lee, G Cull, RG Owen, P Marlton, BE Wahlin, RG Sanz, H McCarthy, S Mulligan, A Tedeschi, JJ Castillo, J Czyz, de Larrea C Fernández, D Belada, E Libby, JV Matous, M Motta, T Siddiqi, M Tani, M Trneny, MC Minnema, C Buske, V Leblond, J Trotman, WY Chan, J Schneider, S Ro, A Cohen, J Huang, M Dimopoulos. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood 2020; 136( 18): 2038– 2050 https://doi.org/10.1182/blood.2020006844 pmid: 32731259
35	L Nastoupil H Lee F Hagemeister JR Westin F Samaniego L Feng J John SG Forbes LE Fayad MR Green RE Davis SS Neelapu NH Fowler. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated subjects with follicular and marginal zone lymphoma: an open label, phase II study. Blood 2018; 132(Supplement 1): 447 doi:10.1182/blood- 2018– 99-113721
36	B Kiesewetter, E Willenbacher, W Willenbacher, A Egle, P Neumeister, D Voskova, ME Mayerhoefer, I Simonitsch-Klupp, T Melchardt, R Greil, M; AGMT Investigators Raderer. A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. Blood 2017; 129( 3): 383– 385 https://doi.org/10.1182/blood-2016-06-720599 pmid: 27879257
37	A Noy, S de Vos, C Thieblemont, P Martin, CR Flowers, F Morschhauser, GP Collins, S Ma, M Coleman, S Peles, S Smith, JC Barrientos, A Smith, B Munneke, I Dimery, DM Beaupre, R Chen. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 2017; 129( 16): 2224– 2232 https://doi.org/10.1182/blood-2016-10-747345 pmid: 28167659
38	P Martin, SH Jung, B Pitcher, NL Bartlett, KA Blum, T Shea, ED Hsi, J Ruan, SE Smith, JP Leonard, BD Cheson. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol 2017; 28( 11): 2806– 2812 https://doi.org/10.1093/annonc/mdx496 pmid: 28945884
39	F Morschhauser, NH Fowler, P Feugier, R Bouabdallah, H Tilly, ML Palomba, C Fruchart, EN Libby, RO Casasnovas, IW Flinn, C Haioun, H Maisonneuve, L Ysebaert, NL Bartlett, K Bouabdallah, P Brice, V Ribrag, N Daguindau, Gouill S Le, GM Pica, Garcia-Sancho A Martin, A López-Guillermo, JF Larouche, K Ando, da Silva M Gomes, M André, P Zachée, LH Sehn, K Tobinai, G Cartron, D Liu, J Wang, L Xerri, GA; RELEVANCE Trial Investigators Salles. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 2018; 379( 10): 934– 947 https://doi.org/10.1056/NEJMoa1805104 pmid: 30184451
40	J Ruan, P Martin, B Shah, SJ Schuster, SM Smith, RR Furman, P Christos, A Rodriguez, J Svoboda, J Lewis, O Katz, M Coleman, JP Leonard. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med 2015; 373( 19): 1835– 1844 https://doi.org/10.1056/NEJMoa1505237 pmid: 26535512
41	ML Wang, S Rule, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, RH Advani, JE Romaguera, ME Williams, JC Barrientos, E Chmielowska, J Radford, S Stilgenbauer, M Dreyling, WW Jedrzejczak, P Johnson, SE Spurgeon, L Li, L Zhang, K Newberry, Z Ou, N Cheng, B Fang, J McGreivy, F Clow, JJ Buggy, BY Chang, DM Beaupre, LA Kunkel, KA Blum. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369( 6): 507– 516 https://doi.org/10.1056/NEJMoa1306220 pmid: 23782157
42	S Rule, M Dreyling, A Goy, G Hess, R Auer, B Kahl, JA Hernández-Rivas, K Qi, S Deshpande, L Parisi, M Wang. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica 2019; 104( 5): e211– e214 https://doi.org/10.3324/haematol.2018.205229 pmid: 30442728
43	Y Song, K Zhou, D Zou, J Zhou, J Hu, H Yang, H Zhang, J Ji, W Xu, J Jin, F Lv, R Feng, S Gao, H Guo, L Zhou, R Elstrom, J Huang, W Novotny, R Wei, J Zhu. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton’s tyrosine kinase. Clin Cancer Res 2020; 26( 16): 4216– 4224 https://doi.org/10.1158/1078-0432.CCR-19-3703 pmid: 32461234
44	A Younes, LH Sehn, P Johnson, PL Zinzani, X Hong, J Zhu, C Patti, D Belada, O Samoilova, C Suh, S Leppä, S Rai, M Turgut, W Jurczak, MC Cheung, R Gurion, SP Yeh, A Lopez-Hernandez, U Dührsen, C Thieblemont, CS Chiattone, S Balasubramanian, J Carey, G Liu, SM Shreeve, S Sun, SH Zhuang, J Vermeulen, LM Staudt, W; PHOENIX investigators Wilson. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol 2019; 37( 15): 1285– 1295 https://doi.org/10.1200/JCO.18.02403 pmid: 30901302
45	J Zhu X Hong Y Song. Ibrutinib + rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) in patients with untreated non-germinal center B-cell-like diffuse large B-cell lymphoma (DLBCL): a Chinese subgroup analysis of the phase 3 PHOENIX trial. Journal of Clinical Oncology, Abstracts of the 23rd Annual Meeting of Chinese Society of Clinical Oncology 2020. 50
46	WH Wilson, RM Young, R Schmitz, Y Yang, S Pittaluga, G Wright, CJ Lih, PM Williams, AL Shaffer, J Gerecitano, S de Vos, A Goy, VP Kenkre, PM Barr, KA Blum, A Shustov, R Advani, NH Fowler, JM Vose, RL Elstrom, TM Habermann, JC Barrientos, J McGreivy, M Fardis, BY Chang, F Clow, B Munneke, D Moussa, DM Beaupre, LM Staudt. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015; 21( 8): 922– 926 https://doi.org/10.1038/nm.3884 pmid: 26193343
47	M Wang, N Fowler, N Wagner-Bartak, L Feng, J Romaguera, SS Neelapu, F Hagemeister, M Fanale, Y Oki, B Pro, J Shah, S Thomas, A Younes, C Hosing, L Zhang, KJ Newberry, M Desai, N Cheng, M Badillo, M Bejarano, Y Chen, KH Young, R Champlin, L Kwak, L Fayad. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 2013; 27( 9): 1902– 1909 https://doi.org/10.1038/leu.2013.95 pmid: 23545991
48	MC Zhang, Y Fang, L Wang, S Cheng, D Fu, Y He, Y Zhao, CF Wang, XF Jiang, Q Song, PP Xu, WL Zhao. Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma. Clin Epigenetics 2020; 12( 1): 160 https://doi.org/10.1186/s13148-020-00948-9 pmid: 33097085
49	MS Lionakis, K Dunleavy, M Roschewski, BC Widemann, JA Butman, R Schmitz, Y Yang, DE Cole, C Melani, CS Higham, JV Desai, M Ceribelli, L Chen, CJ Thomas, RF Little, J Gea-Banacloche, S Bhaumik, M Stetler-Stevenson, S Pittaluga, ES Jaffe, J Heiss, N Lucas, SM Steinberg, LM Staudt, WH Wilson. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell 2017; 31( 6): 833– 843.e5 https://doi.org/10.1016/j.ccell.2017.04.012 pmid: 28552327
50	L Goldwirt, K Beccaria, A Ple, H Sauvageon, S Mourah. Ibrutinib brain distribution: a preclinical study. Cancer Chemother Pharmacol 2018; 81( 4): 783– 789 https://doi.org/10.1007/s00280-018-3546-3 pmid: 29476222
51	C Grommes, A Pastore, N Palaskas, SS Tang, C Campos, D Schartz, P Codega, D Nichol, O Clark, WY Hsieh, D Rohle, M Rosenblum, A Viale, VS Tabar, CW Brennan, IT Gavrilovic, TJ Kaley, CP Nolan, A Omuro, E Pentsova, AA Thomas, E Tsyvkin, A Noy, ML Palomba, P Hamlin, CS Sauter, CH Moskowitz, J Wolfe, A Dogan, M Won, J Glass, S Peak, EC Lallana, V Hatzoglou, AS Reiner, PH Gutin, JT Huse, KS Panageas, TG Graeber, N Schultz, LM DeAngelis, IK Mellinghoff. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov 2017; 7( 9): 1018– 1029 https://doi.org/10.1158/2159-8290.CD-17-0613 pmid: 28619981
52	V Mehta, S Goel, R Kabarriti, D Cole, M Goldfinger, A Acuna-Villaorduna, K Pradhan, R Thota, S Reissman, JA Sparano, BA Gartrell, RV Smith, N Ohri, M Garg, AD Racine, S Kalnicki, R Perez-Soler, B Halmos, A Verma. Case fatality rate of cancer patients with COVID-19 in a New York Hospital System. Cancer Discov 2020; 10( 7): 935– 941 https://doi.org/10.1158/2159-8290.CD-20-0516 pmid: 32357994
53	F Passamonti, C Cattaneo, L Arcaini, R Bruna, M Cavo, F Merli, E Angelucci, M Krampera, R Cairoli, Porta MG Della, N Fracchiolla, M Ladetto, Passerini C Gambacorti, M Salvini, M Marchetti, R Lemoli, A Molteni, A Busca, A Cuneo, A Romano, N Giuliani, S Galimberti, A Corso, A Morotti, B Falini, A Billio, F Gherlinzoni, G Visani, MC Tisi, A Tafuri, P Tosi, F Lanza, M Massaia, M Turrini, F Ferrara, C Gurrieri, D Vallisa, M Martelli, E Derenzini, A Guarini, A Conconi, A Cuccaro, L Cudillo, D Russo, F Ciambelli, AM Scattolin, M Luppi, C Selleri, La Barbera E Ortu, C Ferrandina, Renzo N Di, A Olivieri, M Bocchia, M Gentile, F Marchesi, P Musto, AB Federici, A Candoni, A Venditti, C Fava, A Pinto, P Galieni, L Rigacci, D Armiento, F Pane, M Oberti, P Zappasodi, C Visco, M Franchi, PA Grossi, L Bertù, G Corrao, L Pagano, P; ITA-HEMA-COV Investigators Corradini. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 2020; 7( 10): e737– e745 https://doi.org/10.1016/S2352-3026(20)30251-9 pmid: 32798473
54	Y Xiao Y Cao L Huang M Zheng JF Zhou. Management of patients with hematological malignancies in outbreak areas of COVID-19 epidemic: our experience at Wuhan Tongji Hospital. Chin J Hematol (Zhonghua Xue Ye Xue Za Zhi) 2020; 41(7): 612– 614 (in Chinese)
55	M Roschewski, MS Lionakis, JP Sharman, J Roswarski, A Goy, MA Monticelli, M Roshon, SH Wrzesinski, JV Desai, MA Zarakas, J Collen, K Rose, A Hamdy, R Izumi, GW Wright, KK Chung, J Baselga, LM Staudt, WH Wilson. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol 2020; 5( 48): eabd0110 https://doi.org/10.1126/sciimmunol.abd0110 pmid: 32503877
56	SP Treon, JJ Castillo, AP Skarbnik, JD Soumerai, IM Ghobrial, ML Guerrera, K Meid, G Yang. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood 2020; 135( 21): 1912– 1915 https://doi.org/10.1182/blood.2020006288 pmid: 32302379
57	EA Chong, LE Roeker, M Shadman, MS Davids, SJ Schuster, AR Mato. BTK inhibitors in cancer patients with COVID-19: “The winner will be the one who controls that chaos” (Napoleon Bonaparte). Clin Cancer Res 2020; 26( 14): 3514– 3516 https://doi.org/10.1158/1078-0432.CCR-20-1427 pmid: 32345646
58	AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, A Osterborg, D Wojenski, M Kamdar, SF Huntington, MS Davids, JR Brown, D Antic, R Jacobs, IE Ahn, J Pu, KM Isaac, PM Barr, CS Ujjani, MB Geyer, E Berman, AD Zelenetz, N Malakhov, RR Furman, M Koropsak, N Bailey, L Hanson, GF Perini, S Ma, CE Ryan, A Wiestner, CA Portell, M Shadman, EA Chong, DM Brander, S Sundaram, AN Seddon, E Seymour, M Patel, N Martinez-Calle, T Munir, R Walewska, A Broom, H Walter, D El-Sharkawi, H Parry, MR Wilson, PEM Patten, JÁ Hernández-Rivas, F Miras, Escalada N Fernández, P Ghione, C Nabhan, S Lebowitz, E Bhavsar, J López-Jiménez, D Naya, JA Garcia-Marco, SS Skånland, R Cordoba, TA Eyre. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood 2020; 136( 10): 1134– 1143 https://doi.org/10.1182/blood.2020006965 pmid: 32688395
59	Society of Clinical Oncology (CSCO) Anti-Leukemia Alliance Chinese Society of Clinical Oncology (CSCO) Anti-Lymphoma Alliance Chinese. Chinese expert consensus on the ibrutinib treatment in B-cell malignancies (2019 version). J Leuk Lymphoma (Bai Xue Bing·Lin Ba Liu) 2019; 28( 8): 449– 456 (in Chinese)
60	SE Coutre, JC Byrd, P Hillmen, JC Barrientos, PM Barr, S Devereux, T Robak, TJ Kipps, A Schuh, C Moreno, RR Furman, JA Burger, M O’Dwyer, P Ghia, R Valentino, S Chang, JP Dean, DF James, SM O’Brien. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv 2019; 3( 12): 1799– 1807 https://doi.org/10.1182/bloodadvances.2018028761 pmid: 31196847
61	NH Fowler, RE Davis, S Rawal, L Nastoupil, FB Hagemeister, P McLaughlin, LW Kwak, JE Romaguera, MA Fanale, LE Fayad, JR Westin, J Shah, RZ Orlowski, M Wang, F Turturro, Y Oki, LC Claret, L Feng, V Baladandayuthapani, T Muzzafar, KY Tsai, F Samaniego, SS Neelapu. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 2014; 15( 12): 1311– 1318 https://doi.org/10.1016/S1470-2045(14)70455-3 pmid: 25439689
62	S Garciaz, D Coso, JM Schiano de Colella, R Bouabdallah. Lenalidomide for the treatment of B-cell lymphoma. Expert Opin Investig Drugs 2016; 25( 9): 1103– 1116 https://doi.org/10.1080/13543784.2016.1208170 pmid: 27414850

[1]	Yingying Li, Shiyuan Wang, Mengmeng Lin, Chunying Hou, Chunyu Li, Guohui Li. Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy[J]. Front. Med., 2022, 16(3): 307-321.
[2]	Pooria Safarzadeh Kozani, Pouya Safarzadeh Kozani, Fatemeh Rahbarizadeh. CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success?[J]. Front. Med., 2022, 16(3): 322-338.
[3]	Lei Fan, Li Wang, Lei Cao, Huayuan Zhu, Wei Xu, Jianyong Li. Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients[J]. Front. Med., 2022, 16(2): 285-294.
[4]	Hongyun Zhao, Fan Luo, Jinhui Xue, Su Li, Rui-Hua Xu. Emerging immunological strategies: recent advances and future directions[J]. Front. Med., 2021, 15(6): 805-828.
[5]	Wenjie Zhu, Binghe Xu. Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR⁺/HER2^--) advanced breast cancer: a meta-analysis and systemic review of randomized clinical trials[J]. Front. Med., 2021, 15(2): 208-220.
[6]	Hongnan Mo, Binghe Xu. Progress in systemic therapy for triple-negative breast cancer[J]. Front. Med., 2021, 15(1): 1-10.
[7]	Yong Fan, Yan Geng, Lin Shen, Zhuoli Zhang. Advances on immune-related adverse events associated with immune checkpoint inhibitors[J]. Front. Med., 2021, 15(1): 33-42.
[8]	Ching-Hon Pui. Precision medicine in acute lymphoblastic leukemia[J]. Front. Med., 2020, 14(6): 689-700.
[9]	Bin Gu, Jianhong Chu, Depei Wu. Chimeric antigen receptor T cell therapies for acute myeloid leukemia[J]. Front. Med., 2020, 14(6): 701-710.
[10]	Qiaoshuai Lan, Shuai Xia, Qian Wang, Wei Xu, Haiyan Huang, Shibo Jiang, Lu Lu. Development of oncolytic virotherapy: from genetic modification to combination therapy[J]. Front. Med., 2020, 14(2): 160-184.
[11]	Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao. Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects[J]. Front. Med., 2019, 13(4): 427-437.
[12]	Yumeng Wang, Guiling Li. PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives[J]. Front. Med., 2019, 13(4): 438-450.
[13]	Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy[J]. Front. Med., 2019, 13(1): 57-68.
[14]	Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen. Adoptive cell transfer therapy for hepatocellular carcinoma[J]. Front. Med., 2019, 13(1): 3-11.
[15]	Yiwen Cao, Zhenhua Liu, Wen Wu, Ying Qian, Qin Shi, Rong Shen, Binshen Ouyang, Pengpeng Xu, Shu Cheng, Jin Ye, Yiming Lu, Chaofu Wang, Chengde Yang, Li Wang, Weili Zhao. Presence of multiple abnormal immunologic markers is an independent prognostic factor of diffuse large B-cell lymphoma[J]. Front. Med., 2019, 13(1): 94-103.

Viewed

Full text

Abstract

Cited

Shared

Discussed